While CD16 and NKG2D are among the first to be used for engaging NK cells, NKp46 is becoming a hot target since NKp46 is more sustainably expressed in tumor-infiltrating NK cells, whereas CD16 and NKG2D are frequently down-regulated [149]. Here, FCGR3A is linked to neoplasm.